| Role of the p53-homologue p73 in E2F1-induced apoptosis T Stiewe, BM Pützer Nature genetics 26 (4), 464-469, 2000 | 449 | 2000 |
| The p53 family in differentiation and tumorigenesis T Stiewe Nature Reviews Cancer 7 (3), 165-167, 2007 | 376 | 2007 |
| Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis T Stiewe, CC Theseling, BM Pützer Journal of Biological Chemistry 277 (16), 14177-14185, 2002 | 254 | 2002 |
| Transactivation-deficient ΔTA-p73 acts as an oncogene T Stiewe, S Zimmermann, A Frilling, H Esche, BM Pützer Cancer research 62 (13), 3598-3602, 2002 | 242 | 2002 |
| Gene expression changes in response to E2F1 activation J Stanelle, T Stiewe, CC Theseling, M Peter, BM Pützer Nucleic acids research 30 (8), 1859-1867, 2002 | 227 | 2002 |
| Role of p73 in malignancy: tumor suppressor or oncogene? T Stiewe, BM Pützer Cell Death & Differentiation 9 (3), 237-245, 2002 | 197 | 2002 |
| A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism A Pribluda, E Elyada, Z Wiener, H Hamza, RE Goldstein, M Biton, ... Cancer cell 24 (2), 242-256, 2013 | 192 | 2013 |
| Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells M Michaelis, F Rothweiler, S Barth, J Cinatl, M Van Rikxoort, ... Cell death & disease 2 (12), e243-e243, 2011 | 160 | 2011 |
| The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes M Luu, S Pautz, V Kohl, R Singh, R Romero, S Lucas, J Hofmann, ... Nature communications 10 (1), 1-12, 2019 | 157 | 2019 |
| p53 family members in myogenic differentiation and rhabdomyosarcoma development H Cam, H Griesmann, M Beitzinger, L Hofmann, R Beinoraviciute-Kellner, ... Cancer cell 10 (4), 281-293, 2006 | 138 | 2006 |
| Immune and inflammatory cell composition of human lung cancer stroma GA Banat, A Tretyn, SS Pullamsetti, J Wilhelm, A Weigert, C Olesch, ... PLOS one 10 (9), e0139073, 2015 | 132 | 2015 |
| Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas T Stiewe, S Tuve, M Peter, A Tannapfel, AH Elmaagacli, BM Pützer Clinical cancer research 10 (2), 626-633, 2004 | 120 | 2004 |
| The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic E Kadosh, I Snir-Alkalay, A Venkatachalam, S May, A Lasry, E Elyada, ... Nature 586 (7827), 133-138, 2020 | 116 | 2020 |
| DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis K Schlereth, R Beinoraviciute-Kellner, MK Zeitlinger, AC Bretz, M Sauer, ... Molecular cell 38 (3), 356-368, 2010 | 99 | 2010 |
| p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo O Timofeev, K Schlereth, M Wanzel, A Braun, B Nieswandt, ... Cell reports 3 (5), 1512-1525, 2013 | 89 | 2013 |
| p73 in apoptosis T Stiewe, BM Pützer Apoptosis 6 (6), 447-452, 2001 | 89 | 2001 |
| Antithetical NFAT c1–Sox2 and p53–miR200 signaling networks govern pancreatic cancer cell plasticity SK Singh, NM Chen, E Hessmann, J Siveke, M Lahmann, G Singh, ... The EMBO journal 34 (4), 517-530, 2015 | 86 | 2015 |
| Characterization of the p53 cistrome–DNA binding cooperativity dissects p53's tumor suppressor functions K Schlereth, C Heyl, AM Krampitz, M Mernberger, F Finkernagel, ... PLoS genetics 9 (8), e1003726, 2013 | 86 | 2013 |
| A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome S Reinartz, F Finkernagel, T Adhikary, V Rohnalter, T Schumann, ... Genome biology 17 (1), 1-22, 2016 | 84 | 2016 |
| KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment M Schön, BG Wienrich, S Kneitz, H Sennefelder, K Amschler, V Vöhringer, ... Journal of the National Cancer Institute 100 (12), 862-875, 2008 | 81 | 2008 |
